A multicenter study of efficacy and safety of ramucirumab plus FOLFIRI as second-line treatment for patients with metastatic colorectal cancer previously treated with combination chemotherapy with anti-EGFR antibody

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ramucirumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
Indications Colon cancer; Colorectal cancer; Rectal cancer
Focus Therapeutic Use
Acronyms JACCRO CC-16

Most Recent Events

02 Jul 2022 Results of subgroup analysis of this trial presented at the 24th World Congress on Gastrointestinal Cancer
09 Mar 2022 Primary endpoint (6-month progression-free survival (PFS) rate) has been met, according to Results presented at the 2022 Gastrointestinal Cancers Symposium.
09 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight